Brought to you by
ECR 2018 / C-0245
Follow-up of brain tumors: utility of Fluorine 18-Fluorocholine PET
Congress: ECR 2018
Poster No.: C-0245
Type: Educational Exhibit
Keywords: Neuroradiology brain, CNS, Nuclear medicine, PET, MR, CT, Contrast agent-intravenous, Staging, Treatment effects, Multidisciplinary cancer care, Cancer, Neoplasia
Authors: J. J. Delgado Moraleda, P. Sopena-Novales, S. Brugger, P. Oliván Sasot, A. M. Yepes Agudelo, A. ALEGRE DELGADO; Valencia/ES


1.Bolcaen J, Acou M, Boterberg T, Vanhove C, De Vos F, Van den Broecke C, et al. 18F-PET and MRI FCho for the prediction of response in glioblastoma Patients ACCORDING TO the RANO criteria. Nucl Med Commun. 2017 Mar; 38 (3): 242-9.


2. Kwee SA, Ko JP, Jiang CS, MR Watters, MN Coel. Solitary brain lesions at MR imaging Enhancing: evaluation With Fluorine 18 fluorocholine PET. Radiology. 2007 Aug; 244 (2): 557-65.


3. Mertens K, J Bolcaen, Ham H, Deblaere K, Van den Broecke C, Boterberg T, et al. The optimal timing for brain imaging and other brain lesions Tumors With 18F-Labeled fluoromethylcholine: a dynamic positron emission tomography study. Nucl Med Commun. 2012 Sep; 33 (9): 954-9.


4. Treglia G, Giovannini E, Di Franco D, Calcagni ML, Rufini V, Picchio M, et al. The role of positron emission tomography using carbon-11 and fluorine-18 in tumors other than choline prostate cancer: a systematic review. Ann Nucl Med 2012 Jul; 26 (6):. 451-61.



5. Hara T, Kondo T, Hara T, Kosaka N. Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J Neurosurg. 2003 Sep; 99 (3): 474-9.

POSTER ACTIONS Add bookmark Contact presenter Send to a friend Download pdf
2 clicks for more privacy: On the first click the button will be activated and you can then share the poster with a second click.

This website uses cookies. Learn more